(Press-News.org) As a result of research performed by scientists at the University of Maryland School of Medicine (UM SOM), the U.S. Food and Drug Administration has approved the use of a drug to treat the deleterious effects of radiation exposure following a nuclear incident. The drug, Neupogen®, is the first ever approved for the treatment of acute radiation injury.
The research was done by Thomas J. MacVittie, PhD, professor, and Ann M. Farese, MA, MS, assistant professor, both in the University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology's Division of Translational Radiation Sciences. The investigators did their research in a non-human clinical model of high-dose radiation.
"Our research shows that this drug works to increase survival by protecting blood cells," said Dr. MacVittie, who is considered one of the nation's leading experts on radiation research. "That is a significant advancement, because the drug can now be used as a safe and effective treatment for the blood cell effects of severe radiation poisoning."
Radiation damages the bone marrow, and as a result decreases production of infection-fighting white blood cells. Neupogen® counteracts these effects. The drug, which is made by Amgen, Inc., was first approved in 1991 to treat cancer patients receiving chemotherapy. Although doctors may use it "off label" for other indications, the research and the resulting approval would speed up access to and use of the drug in the event of a nuclear incident.
This planning is already under way. In 2013, the Biomedical Advanced Research and Development Authority (BARDA), an arm of the Department of Health and Human Services, bought $157 million worth of Neupogen® for stockpiles around the country in case of nuclear accident or attack.
Neupogen® is one of several "dual-use" drugs that are being examined for their potential use as countermeasures in nuclear incidents. These drugs have everyday medical uses, but also may be helpful in treating radiation-related illness in nuclear events. Dr. MacVittie and Ms. Farese are continuing their research on other dual-use countermeasures to radiation. They are now focusing on remedies for other aspects of radiation injury, including problems with the gastrointestinal tract and the lungs.
The research builds on 40 years of work that Dr. MacVittie and his team have conducted in the field of radiation research, during which they have helped to define the field. The Neupogen study is also part of a broad portfolio of research being conducted by faculty in the Department of Radiation Oncology. Among these are Minesh Mehta, MD, the medical director of the Maryland Proton Treatment Center, who is focusing on research into thoracic oncology, neuro-oncology, integrating imaging advances with radiation therapy, and innovative applications of new radiation therapy technologies to test biological concepts. Another researcher in the department is Zeljko Vujaskovic, MD, PhD, director of the Division of Translational Radiation Sciences; he is doing research on identifying potential biomarkers predicting individual patient risk for injury, and to develop novel therapeutic interventions/strategies to prevent, mitigate, or treat radiation injury.
"In terms of both research and treatment, our department is leading the way in developing the most effective discovery-based clinical applications to help protect and heal patients," says William F. Regine, MD, professor and Isadore & Fannie Schneider Foxman Endowed Chair in Radiation Oncology at the UM SOM.
He added that research has served as the foundation for the Department of Radiation Oncology's recent development of four clinical modalities for the treatment of cancer through radiation:
Proton Treatment, a precise approach to cancer, which targets tumors while minimizing harm to surrounding tissues. Proton treatment uses protons traveling at about two-thirds the speed of light to precisely deliver beams of radiation to the tumor. This treatment will be available in the new 110,000 sq ft Maryland Proton Treatment Center before the end of the year;
Selective Internal Radiation Therapy, a precision modality for treating patients with particularly difficult to remove tumors involving the liver such as those from colorectal cancers;
Gammapod, a new, high-precision, noninvasive method of treating early-stage breast cancer;
Thermal Therapies, the use of "heat" in treating a broad spectrum of malignancies.
"The Department of Radiation Oncology's work is just one example of how the School of Medicine is discovering innovative ways to repurpose existing drugs that are able fight a broader array of critical diseases," said Dean E. Albert Reece, MD, PhD, MBA, who is also the vice president for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor and Dean of the School of Medicine. "We are particularly proud of the Neupogen research as it is not only important scientifically; it is crucial for our country's public health and its national security."
INFORMATION:
About the University of Maryland School of Medicine
The University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine. The School of Medicine is the founding school of the University of Maryland and is an integral part of the 12-campus University System of Maryland. Located on the University of Maryland's Baltimore campus, the School of Medicine works closely with the University of Maryland Medical Center and Medical System to provide a research-intensive, academic and clinically based education. With 43 academic departments, centers and institutes and a faculty of more than 3,000 physicians and research scientists plus more than $400 million in extramural funding, the School is regarded as one of the leading biomedical research institutions in the U.S. with top-tier faculty and programs in cancer, brain science, surgery and transplantation, trauma and emergency medicine, vaccine development and human genomics, among other centers of excellence. The School is not only concerned with the health of the citizens of Maryland and the nation, but also has a global presence, with research and treatment facilities in more than 35 countries around the world.
MANHATTAN , Kansas -- A recent study with Kansas State University researchers details vaccine development for two new strains of avian influenza that can be transmitted from poultry to humans. The strains have led to the culling of millions of commercial chickens and turkeys as well as the death of hundreds of people.
The new vaccine development method is expected to help researchers make vaccines for emerging strains of avian influenza more quickly. This could reduce the number and intensity of large-scale outbreaks at poultry farms as well as curb human transmission.
It ...
New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.
Working with colleagues at the Mayo Clinic in Rochester, Minnesota and the MD Anderson Cancer Center in Dallas, Texas, Michael Chuong, MD, an assistant professor of radiation oncology at the school, compared two kinds of X-ray radiation with proton therapy, an innovative, precise approach that targets tumors while minimizing ...
May 22, 2015 - Boston, MA - Few professions in the world benefit from the sharing of information as much as meteorology. Nearly all countries around the world realize the value of sharing meteorological data across their borders. This information collaboration is vital to scientific understanding of the atmosphere and the oceans, as well as essential for accurate forecasts and timely warnings of hurricanes, typhoons, and other severe weather.
But what about when one country maintains an active embargo with another country?
That question was answered last year, when ...
BUFFALO, N.Y. -- It looks like a Slinky suspended in motion.
Yet this photonics advancement -- called a metamaterial hyperlens -- doesn't climb down stairs.
Instead, it improves our ability to see tiny objects.
Described in a research paper published today by the journal Nature Communications, the hyperlens may someday help detect some of the most lethal forms of cancer.
It could also lead to advancements in nanoelectronic manufacturing and boost scientists' ability to examine single molecules -- a development with implications in physics, chemistry, biology and other ...
WASHINGTON, D.C. -- Disaster investigators and emergency personnel may find themselves better able to assess and respond to terrorist attacks and industrial accidents with the aid of a new computational tool that determines the energy from explosions near the Earth's surface. As a first test of the new approach, its developers have analyzed a deadly explosion which reportedly killed dozens of regime soldiers in the Syrian civil war.
Computing the energy yield of an explosion just below, at, or above the ground poses difficult challenges, while deep-underground blasts ...
New York, NY -- May 22, 2015 -- Working with researchers at Zhejiang University in China, Changxi Zheng, assistant professor of computer science at Columbia Engineering, has developed a technique that enables hydrographic printing, a widely used industrial method for transferring color inks on a thin film to the surface of manufactured 3D objects, to color these surfaces with the most precise alignment ever attained. Using a new computational method they developed to simulate the printing process, Zheng and his team have designed a model that predicts color film distortion ...
(NEW YORK - May 22) - By comparing flu viruses to the virus that causes measles, researchers fine-tuned a tool that may enable faster vaccine design, according to a study led by Mount Sinai researchers and published online this week in the journal Cell Reports.
The study results revolve around viruses, which are designed perfectly by evolution to invade human cells, inject viral genes and use human genetic machinery to make copies of them. In an endless back and forth, human immune cells have evolved to recognize and attack viral surface proteins, and viruses to constantly ...
(PARIS, FRANCE) Technique, talk, and talent were three buzzwords at the 2015 EuroPCR congress. As in years past, the conference featured a mix of breaking news, live case demonstrations, oral and poster sessions, debates, and tips-and-tricks tutorials. New study data have been increasingly showcased at EuroPCR and this year's meeting featured over 70 new abstract sessions throughout the four-day meeting, across five interventional tracks.
One of the focus topics at this year's meeting was a spate of recent trials showing a benefit for mechanical thrombectomy in acute ...
URBANA, Ill. - The widespread evolution of herbicide-resistant weeds is costing farmers, especially through decreases in productivity and profitability. Although researchers and industry personnel have made recommendations to slow this evolution, an understanding of the patterns and causes of the resistance has been limited.
Diversifying the herbicide mechanisms of action (MOAs) has been recommended to stop the spread of herbicide-resistant weeds. MOAs refer to the biochemical interaction that affects or disrupts the target site in the weed. Two common methods of diversifying ...
The first definitive summary of the best and safest blood pressure lowering treatments for kidney disease and diabetes patients has been compiled by New Zealand doctor and researcher Associate Professor Suetonia Palmer.
The international relevance of her work for doctors, patients and those who decide which drugs to fund has been demonstrated by the prestigious Lancet medical journal publishing an article on her study in its latest edition.
The University of Otago, Christchurch, researcher together with a global team used innovative statistical analysis to compare hundreds ...
